Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

Autor: A. Palumbo, A. Waage, C. Hulin, M. Beksac, S. Zweegman, F. Gay, P. Gimsing, X. Leleu, P. Wijermans, G. Sucak, S. Pezzatti, G. Juliusson, B. Pegourie, M. Schaafsma, M. Galli, I. Turesson, B. Kolb, B. van der Holt, I. Baldi, J. Rolke, G. Ciccone, M. Wetterwald, H. Lokhorst, M. Boccadoro, P. Rodon, P. Sonneveld

Publikováno v: Haematologica, 98(1), 87-94. Ferrata Storti Foundation
Palumbo, A, Waage, A, Hulin, C, Beksac, M, Zweegman, S, Gay, F, Gimsing, P, Leleu, X, Wijermans, P, Sucak, G, Pezzatti, S, Juliusson, G, Pegourie, B, Schaafsma, M, Galli, M, Turesson, I, Kolb, B, van der Holt, B, Baldi, I, Rolke, J, Ciccone, G, Wetterwald, M, Lokhorst, H, Boccadoro, M, Rodon, P & Sonneveld, P 2013, ' Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials ', Haematologica, vol. 98, no. 1, pp. 87-94 . https://doi.org/10.3324/haematol.2012.067058
Haematologica

Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and is now considered a standard of care for patients not eligible for transplantation. However, this treatment is a major source of morbidity. A m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b462135b7460d937fe6f07b00499f652
https://pure.eur.nl/en/publications/aca0c548-4375-41e5-93f6-749b61264205

A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myelomaa prospective randomised phase III study

Autor: M VANAGTHOVEN, C SEGEREN, I BUIJT, C UYLDEGROOT, B VANDERHOLT, H LOKHORST, P SONNEVELD

Publikováno v: European Journal of Cancer. 40:1159-1169

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::62090b0caf6f041bffdcdcbe018624ce
https://doi.org/10.1016/s0959-8049(04)00128-5

Revised-international staging system (R-ISS): A new and simple prognostic assessment for multiple myeloma

Autor: S., Oliva, S., Caltagirone, R., Passera, B., Van Der Holt, I., Hardan, A., Nozza, E., Zamagni, P., Musto, P., Omede, S., Zweegman, L., Baldini, S., Bringhen, H., Lokhorst, R., Ria, R., Zambello, M., Ruggeri, A., Broijl, S., Pezzatti, R., Hajek, P., Tacchetti, S., Pozzi, P., Cornelissen, A., Spencer, M., Boccadoro, M., Cavo, P., Sonneveld

Publikováno v: S., O, S., C, R., P, B., V D H, I., H, A., N, E., Z, P., M, P., O, S., Z, L., B, S., B, H., L, R., R, R., Z, M., R, A., B, S., P, R., H, P., T, S., P, P., C, A., S, M., B, M., C & P., S 2014, ' Revised-international staging system (R-ISS): A new and simple prognostic assessment for multiple myeloma ', Haematologica, vol. 99, no. SUPPL. 1, pp. 496 . < http://www.haematologica.org/content/99/supplement_1/1.full.pdf+html http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=71700764 >
Haematologica, 99(SUPPL. 1). Ferrata Storti Foundation

Background: Multiple myeloma (MM) is a heterogeneous disease and the thought that there are different diseases with variable outcome led to a definition of prognostic tools. The International Staging System (ISS) is a simple and widely used staging m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::2d74e04dab0f703a2b1818e1836a9766
https://research.vumc.nl/en/publications/07a84790-a099-465a-a7f5-601cf8afacfb

[Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]

Autor: H, Lokhorst, P C, Huijgens, R, Raymakers, G M J, Bos, E, Vellenga, P W, Wijermans, P, Sonneveld

Publikováno v: Nederlands tijdschrift voor geneeskunde. 149(15)

The treatment for multiple myeloma has undergone many changes over the past decade. Intensive therapy with autologous stem-cell support has improved the clinical outcome significantly in younger patients. Reduced intensity conditioning regimens have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::540afe3911269f898eb0b8b2b97fd4df
https://pubmed.ncbi.nlm.nih.gov/16078776

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914)

Autor: P, Sonneveld, S, Suciu, P, Weijermans, M, Beksac, R, Neuwirtova, G, Solbu, H, Lokhorst, J, van der Lelie, H, Dohner, H, Gerhartz, C M, Segeren, R, Willemze, B, Lowenberg

Publikováno v: British journal of haematology. 115(4)

Patients with multiple myeloma (MM) refractory to alkylating agents frequently express P-glycoprotein (Pgp), which is associated with the multidrug resistance (MDR) phenotype. We have conducted a randomized phase II/III study of the MDR reversal agen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a7ee56990e99b4794a09039a18596574
https://pubmed.ncbi.nlm.nih.gov/11843823